Agilent Technologies, Inc. · NYSE:A

Agilent Technologies — Q4 2022 Earnings Presentation

10 slides from Agilent Technologies's earnings presentation, Nov 21, 2022

  1. Slide 1: Agilent Technologies Q4'22 Financial Results Overview

    Agilent Technologies Q4’22 Financial Results Overview

  2. Slide 2: Safe Harbor

    Safe Harbor These presentations contain forward-looking statements (including, without limitation, information, and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth

  3. Slide 3: Agilent Results Q4'22

    Agilent Results Q4’22 A leading lab partner with unsurpassed capabilities and scale Q4’22 Financial Metrics Q4’22 Highlights • Revenues: $1.85B, +11.4% reported, • Growth: Continued excellent performance across Pharma and broad strength +17.5% y/y core(1)(2) (-6.2% FX,+0.1% M&A). in the applied mark

  4. Slide 4: Agilent Results FY'22

    Agilent Results FY’22 FY22 Financial Metrics FY22 Highlights • Revenues: $6.85B, +8.4% reported, • Growth: Pharma and CAM, our two largest markets, delivered strong +11.9% y/y core(1)(2) (-3.6% FX, +0.1% M&A). results all year long. Broad strength across our geographic regions, • Operating Margin: 2

  5. Slide 5: Growth in a $65B+ Market – Q4'22 Core Growth Results by End Market

    Growth in a $65B+ Market – Q4’22 Core Growth(2) Results by End Market Continued momentum in Pharma and CAM supported by robust growth in Food and Environmental & Forensics  Pharma & Biotech: Up 20% on broad strength across large and small molecule globally.  Chemicals & Advanced Materials: Up 27%

  6. Slide 6: Life Sciences & Applied Markets Group (LSAG)

    Life Sciences & Applied Markets Group (LSAG) Instrumentation, Informatics, and • Q4 core revenue performance reflected strength across Consumables our end markets, with Pharma, Chemicals & Advanced for Analytical Laboratories Materials, Food, and Environmental & Forensics all registering 20%+ growth

  7. Slide 7: Agilent CrossLab Group (ACG)

    Agilent CrossLab Group (ACG) Analytical Laboratory • CrossLab delivered another stellar quarter of Services double-digit growth in Q4. The value proposition offered by our world-class service team continues to resonate with customers. Another +1ppt YOY increase in service agreement attach rate in Q4

  8. Slide 8: Diagnostics and Genomics Group (DGG)

    Diagnostics and Genomics Group (DGG) • Q4 core revenue growth of 8% was driven by NASD and Pathology, Genomics, and Nucleic Acid Manufacturing our Genomics portfolio. China continues to be a significant growth opportunity for DGG, growing 20%+ during the quarter. • Featured the new SureSelect Clinic

  9. Slide 9: Q1'23 and FY23 Guidance and Forward-looking Considerations

    Q1’23 and FY23 Guidance and Forward-looking Considerations Based on October 31, 2022 Exchange Rates Q1’23 Guidance (1) FY’23 Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,680 $1,700 Net Revenue ($M) $6,900 $7,000 Y/Y Core Revenue Growth (2) 6.8% 8.0% Y/Y Core Revenue Growth (2)

  10. Slide 10: Q4'22 Financial Results Overview

    11/21/2022 Q4'22 Financial Results Overview

Agilent Technologies — Q4 2022 Earnings Presentation on 6ix